Validity of the Vyntus CPX Metabolic Cart for Assessing Postprandial Energy Expenditure and Respiratory Exchange Ratio
NCT ID: NCT05100797
Last Updated: 2021-12-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
12 participants
OBSERVATIONAL
2021-12-20
2022-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aim 1: In-vitro measures to determine the validity, precision and accuracy of the Vyntus CPX metabolic cart assessed by:
1.1. Methanol burning tests. 1.2. Pure gas (nitrogen \[N2\] and carbon dioxide \[CO2\]) infusions to simulate both, constant and variable fluxes of oxygen consumption (VO2) and carbon dioxide production (VCO2) in different conditions and moments.
1. Immediately after or prior the methanol burning test (in a randomized order).
2. In separate days and time-periods.
Aim 2: In-vivo measures using the Vyntus CPX metabolic cart:
2.1. To assess the resting metabolic rate (RMR or resting energy expenditure \[REE\]) and respiratory exchange ratio (RER) day-to-day biological reproducibility (i.e. reliability) of the metabolic cart.
2.2. Further, the investigators will use an oral glucose tolerance test (OGTT) to determine the post-prandial day-to-day biological reproducibility (especifically the post-prandial RER) of the metabolic cart.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
EXPERIMENT 1 (AIM 1.1 AND 1.2.A):
The investigators will determine the Vyntus CPX measurement error over 14 different days by using both, methanol burnings and pure gas infusions. The order will be random.
1. Methanol burning: the investigators will burn the methanol inside the glass-cage and the investigators will measure dynamically the weight of burned alcohol; gas exchange will be continuously measured with the Vyntus CPX while the produced gases are directed into the metabolic cart's hose tube. The burning will take approximately 25-30 minutes and is expected to produce a RER=0.667.
2. Pure gas infusions: Pure N2 (concentration ≥99.9997%) for diluting ambient O2 and CO2 (concentration ≥99.995%) will be infused using high-precision mass-flow controllers (358 Series, Analyt-MTC, Müllheim, Germany; 0-2 l/min) into the metabolic cart's hose tube. The infused volumes of N2 and CO2 will be selected to replicate (i.e. mimic) as much as possible the VO2 and VCO2 produced by the methanol burning test. The gas infusions will last 20 minutes.
EXPERIMENT 2 (AIM 1.2.B):
The investigators will determine the Vyntus CPX measurement error over 14 different days by using pure gas infusions (each pure gas infusion will last 20 minutes). The procedures will be as follow:
1. Pure gas infusions varying, in a random order, the simulated VO2 and VCO2 to poduce different energy expenditure (EE) and RER values: the investigators will infuse pure N2 and CO2 gases at different volumes. The infusions will be performed either in the morning or in the afternoon (i.e. random) in 14 different and separate days. The randomly selected simulated EE will range between 1000 and 2000 kilocalories per day (kcal/day) while the RER will range between 0.80 and 0.95. The investigators will perform 5 pure gas infusions per day.
2. Pure gas infusions varying, in a random order, the simulated VO2 and VCO2 to produce different EE values while keeping a constant RER: the investigators will infuse pure N2 and CO2 gases at different volumes. The infusions will be performed either in the morning or in the afternoon (i.e. random) in 14 different and separate days. The randomly selected simulated EE will range between 1000 and 2000 kcal/day while the RER is fixed at 0.85. The investigators will perform 5 pure gas infusions per day.
3. Pure gas infusions varying, in a random order, the simulated VO2 and VCO2 to produce different RER values while keeping a constant EE: the investigators will infuse pure N2 and CO2 gases at different volumes. The infusions will be performed either in the morning or in the afternoon (i.e. random) in 14 different and separate days. The randomly selected simulated RER will range between 0.80 and 0.95 while the EE is fixed at 1500 kcal/day. The investigators will perform 5 pure gas infusions per day.
EXPERIMENT 3 (AIM 2.1 and 2.2.):
The investigators will assess the RMR and RER of 10-15 young-healthy adults using the Vyntus CPX metabolic cart on two consecutive days in the morning. The assessment will last 30 minutes and will be performed in agreement with current guidelines. The subjects will lay on a reclined bed in supine position and covered by a bed sheet for 20 minutes before the assessment as an 'acclimation period'. Immediately after this acclimation period the RMR and RER assessment will start under the same conditions. Then, the glucose beverage (75g of glucose/200ml) is given to the participants and another 180 minutes of assessment are performed.
In addition, the participants' weight, height and body composition (using a dual X-ray absorptiometry scan \[DXA scan\]) will be measured upon arrival on the first visit. Blood samples will be collected at different time periods to determine the blood glucose concentration. Lastly, participants will be asked to consume a standardized dinner (specifically designed by a dietitians team) the night before each study day.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vyntus CPX
To study the validity, precision and accuracy of the Vyntus CPX metabolic cart using both, in-vitro and in-vivo (i.e., human study) measures.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-40 y.
* BMI between 18.5 kg/m2 and 30 kg/m2 (both inclusive).
* Willing to fast and not to consume non-caloric stimulant for 12h before the assessments.
* Willing to avoid moderate or vigorous physical activity during 24-48h respectively.
* Have a stable body weight over the last 3 months (changes ≤3 kg) and not being enrolled in a weight loss program.
Exclusion Criteria
* Diagnosed with diabetes.
* Previous bariatric surgery (or other surgeries) for obesity or weight loss.
* Use of medications affecting metabolism or sleep.
* History of neurological disease.
* History of cardiovascular disease, including hypertension, or other chronic diseases.
* Pregnant, planning to become pregnant, or breastfeeding.
* Adherence to special restrained diets (e.g., low-carbohydrates, low-fat, or vegetarian/vegan diets) over the last 3 months.
* Claustrophobia impeding to stay calm under a plastic canopy.
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad de Granada
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonatan Ruiz Ruiz
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Granada
Granada, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jonatan Ruiz Ruiz, Dr.
Role: primary
Juan Manuel Alcántara Alcántara, Dr.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2190/CEIH/2021
Identifier Type: -
Identifier Source: org_study_id